| Literature DB >> 35284415 |
Zhiyao Ma1, David Xinzheyang Li1,2, Melanie Kunze1, Aillette Mulet-Sierra1, Lindsey Westover3, Adetola B Adesida1.
Abstract
Background: Osteoarthritis (OA) primarily affects mechanical load-bearing joints. The knee joint is the most impacted by OA. Knee OA (KOA) occurs in almost all demographic groups, but the prevalence and severity are disproportionately higher in females. The molecular mechanism underlying the pathogenesis and progression of KOA is unknown. The molecular basis of biological sex matters of KOA is not fully understood. Mechanical stimulation plays a vital role in modulating OA-related responses of load-bearing tissues. Mechanical unloading by simulated microgravity (SMG) induced OA-like gene expression in engineered cartilage, while mechanical loading by cyclic hydrostatic pressure (CHP), on the other hand, exerted a pro-chondrogenic effect. This study aimed to evaluate the effects of mechanical loading and unloading via CHP and SMG, respectively, on the OA-related profile changes of engineered meniscus tissues and explore biological sex-related differences.Entities:
Keywords: cyclic hydrostatic pressure; disease modelling; human-engineered meniscus; mechanical stimulation; simulated microgravity
Year: 2022 PMID: 35284415 PMCID: PMC8904202 DOI: 10.3389/fbioe.2022.823679
Source DB: PubMed Journal: Front Bioeng Biotechnol ISSN: 2296-4185
FIGURE 1Experiment outlines. Created with Biorender.com (2021).
Non-identifying donor information.
| Sex | Donor number | Age | Population doubling (PD) |
|---|---|---|---|
| Female | F1 | 33 | 2.687 |
| F2 | 44 | 2.380 | |
| F3 | 30 | 2.774 | |
| F4 | 28 | 3.860 | |
| Male | M1 | 19 | 3.349 |
| M2 | 45 | 2.699 | |
| M3 | 22 | 3.247 | |
| M4 | 35 | 2.149 |
FIGURE 3Effect of CHP and SMG on the chondrogenic and hypertrophic differentiation potential of female and male donors. (A) Histological and immunofluorescent staining analysis. (B) Regulation of selected genes expression level. Gene expression level of individual samples were measured by RT-qPCR. Fold change of expression level was calculated by normalizing expression level in the CHP or SMG group to its corresponding static group. Scale bar: 100 μm *Represents p < 0.05.
FIGURE 4Effect of CHP and SMG on chondrogenesis related factors of female and male donors (A) Biochemical and morphological analysis; contraction is calculated as the % of area lost as compared to the original area. No statistical analysis was conducted for the contraction data with the male SMG group due to limited data points (B) Mechanical property analysis. No statistical analysis was conducted for the mechanical property data with the male SMG group due to limited data points (C) Pearson correlation heatmap of analyzed factors. Fold change value of characterized factors was calculated by normalizing the CHP or SMG group to its corresponding static group. Heatmap was generated by calculating the pairwise Pearson correlation coefficient of included factors. *Represents p < 0.05.
FIGURE 2Effect of CHP and SMG on the transcriptome profile alteration of engineered meniscus tissues. (A) Overlap of differentially expressed genes (DEGs) by CHP and SMG. (B) Top non-redundant Gene Ontology (GO) terms enriched by DEGs of CHP and SMG. DEGs were identified based on all 8 donors. Top significant enriched GO terms were selected by p-value and plotted to the number of genes included in each term.
Top 20 genes with the highest absolute fold change participating in the ECM relevant activities in CHP and SMG groups as compared to static controls.
|
| Description |
| Fold change: CHP vs static |
|---|---|---|---|
|
| Epiregulin | 1.20E-06 | 19.10 |
|
| Neuropilin And Tolloid Like 1 | 2.53E-08 | 7.98 |
|
| Matrix metallopeptidase 3 | 1.22E-06 | 6.47 |
|
| Matrix metallopeptidase 10 | 1.14E-03 | 4.54 |
|
| Somatomedin B And Thrombospondin Type 1 Domain Containing | 7.88E-04 | 3.97 |
|
| C-C Motif Chemokine Ligand 2 | 8.18E-07 | 3.62 |
|
| Urocortin 2 | 5.86E-05 | 3.61 |
|
| Phospholipase A2 Group IIA | 7.00E-04 | 3.60 |
|
| Olfactomedin Like 2A | 1.15E-03 | 3.45 |
|
| C-X-C Motif Chemokine Ligand 13 | 1.00E-03 | 3.40 |
|
| Secreted Frizzled Related Protein 2 | 1.17E-05 | −4.07 |
|
| Adrenomedullin | 1.34E-06 | −4.49 |
|
| Carboxypeptidase X, M14 Family Member 1 | 1.95E-04 | −4.53 |
|
| Selenoprotein P | 3.90E-03 | −5.82 |
|
| FAM20A Golgi Associated Secretory Pathway pseudokinase | 2.24E-03 | −5.92 |
|
| Myeloid Cell Nuclear Differentiation Antigen | 4.02E-03 | −5.99 |
|
| Signal Peptide, CUB Domain And EGF Like Domain Containing 1 | 3.28E-03 | −7.06 |
|
| Secreted Frizzled Related Protein 4 | 6.83E-04 | −8.17 |
|
| Odontogenesis Associated Phosphoprotein | 3.30E-03 | −9.07 |
|
| Apolipoprotein E | 3.30E-07 | −14.78 |
FIGURE 5Transcriptome response of female and male donors to CHP and SMG. (A) Overlap of DEGs of female and male donors exposed to CHP and SMG. (B) Top enriched KEGG pathways by identified DEGs. KEGG terms were selected by p-value and plotted to the enrichment score.
Key enriched KEGG pathways and associated differentially expressed genes (DEGs) in CHP and SMG groups as compared to static controls within female and male donor cohorts. *q < 0.05, **q < 0.01, ***q < 0.001 represent statistical difference of the two groups in each fold change value.
|
| Description | Fold change: CHP/Static | Fold change: SMG/Static | ||||
|---|---|---|---|---|---|---|---|
| Female | Male | Combined | Female | Male | Combined | ||
| KEGG: Mineral absorption | |||||||
| | Ferritin Heavy Chain 1 | 2.18* | 3.47* | 1.70* | 3.47* | 2.32* | 2.77*** |
| | Heme oxygenase 1 | 2.94* | 3.51** | 2.83*** | 3.51** | 3.28** | 3.38*** |
| | Metallothionein 1E | 2.79** | 1.96* | 2.48*** | 1.96* | −1.09 | 1.32 |
| | Metallothionein 1G | 8.25* | 3.29 | 9.38** | 3.29 | 1.11 | 2.21 |
| | Metallothionein 1M | 2.59** | 1.89* | 2.20*** | 1.89* | −1.35 | 1.14 |
| | Metallothionein 2A | 2.59* | 1.57 | 2.79*** | 1.57 | 1.18 | 1.35 |
| | Solute Carrier Family 30 Member 1 | 2.21** | 2.03* | 1.70** | 2.03* | 1.23 | 1.57** |
| | Solute Carrier Family 8 Member A1 | −2.13 | 1.15* | −1.44 | 1.15* | −3.13* | −2.91** |
| KEGG: Wnt signaling pathway | |||||||
| | FOS Like 1, AP-1 Transcription Factor Subunit | 2.99* | 3.88** | 3.44*** | 1.16 | 1.88 | 1.53 |
| | Frizzled Class Receptor 2 | −2.22* | −1.25 | −1.68* | −1.48 | −1.12 | −1.30 |
| | Notum, Palmitoleoyl-Protein carboxylesterase | 6.71* | 1.77 | 2.97* | 1.17 | −1.94 | −1.48 |
| | Secreted Frizzled Related Protein 2 | −6.22* | −3.03* | −4.07** | −2.55 | −3.15 | −2.82* |
| KEGG: HIF-1 signaling pathway | |||||||
| | Egl-9 Family Hypoxia Inducible Factor 3 | 1.00 | 2.49 | 1.58 | −4.24* | −5.75* | −4.72*** |
| | Enolase 2 | −1.24 | 1.48 | 1.11 | −2.96* | −2.51 | −2.74** |
| | Glyceraldehyde-3-Phosphate dehydrogenase | −1.14 | 1.24 | 1.06 | −2.27* | −2.21 | −2.24** |
| | Hexokinase 2 | -1.61 | 1.03 | −1.21 | −2.20* | −2.66* | −2.41** |
| | Heme oxygenase 1 | 2.94* | 2.74* | 2.83*** | 3.51** | 3.28** | 3.38*** |
| | Lactate dehydrogenase A | 1.21 | 1.31 | 1.26 | −1.94* | −2.04* | −1.98*** |
| | Pyruvate dehydrogenase kinase 1 | −1.28 | −1.13 | −1.20 | −2.89** | −3.43** | −3.11*** |
| | 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3 | −1.80 | −1.15 | −1.44 | −2.33* | −2.34* | −2.33** |
| | Phosphoglycerate kinase 1 | 1.17 | 1.23 | 1.20 | −2.04* | −2.24* | −2.13*** |
| | Transferrin Receptor | 2.80** | 1.36 | 1.92** | 2.55** | 2.22* | 2.35*** |
| | Vascular Endothelial Growth Factor A | −1.57 | −1.11 | −1.33 | −5.48** | -5.95* | −5.68*** |
| KEGG: IL-17 signaling pathway | |||||||
| | C-C Motif Chemokine Ligand 2 | 3.85* | 3.48** | 3.62*** | 3.51** | 1.41 | 2.17** |
| | FosB Proto-Oncogene, AP-1 Transcription Factor Subunit | 137.8* | 9.70 | 49.48** | 2.82 | 3.66 | 3.40 |
| | FOS Like 1, AP-1 Transcription Factor Subunit | 2.99* | 3.88** | 3.44*** | 1.16 | 1.88 | 1.53 |
| | Mitogen-Activated Protein kinase 13 | −1.51 | 1.31 | −1.07 | −3.05* | −3.01* | −3.03*** |
| | Matrix metallopeptidase 13 | 1.56* | 1.38 | 1.51 | 1.64 | 2.57* | 1.89** |
| | Matrix metallopeptidase 3 | 10.5** | 4.36 | 6.47*** | −1.80 | −3.99* | −2.82** |
| KEGG: Fluid Shear stress and atherosclerosis | |||||||
| | C-C Motif Chemokine Ligand 2 | 3.85* | 3.48** | 3.62*** | 3.51** | 1.41 | 2.17** |
| | Heme oxygenase 1 | 2.94** | 2.74** | 2.83*** | 3.51** | 3.28** | 3.38*** |
| | Mitogen-Activated Protein kinase kinase 5 | −1.37 | −1.39 | −1.38 | 2.38* | 1.49 | 1.87** |
| | Mitogen-Activated Protein kinase 13 | −1.51 | 1.31 | −1.07 | −3.05* | −3.01* | −3.03*** |
| | Microsomal Glutathione S-Transferase 1 | 2.21** | 1.40 | 1.65** | 1.86* | 1.25 | 1.43** |
| | NAD(P)H Quinone dehydrogenase 1 | 3.83*** | 2.40** | 2.88*** | 4.04*** | 2.42** | 2.97*** |
| | Plasminogen Activator, Tissue Type | 1.51 | 2.27 | 1.88* | 2.51* | 2.43* | 2.47** |
| | Protein kinase AMP-Activated Catalytic Subunit Alpha 2 | −1.37 | 1.44 | 1.03 | −4.63* | -2.90 | −3.70** |
| | Vascular Endothelial Growth Factor A | −1.57 | −1.11 | −1.33 | −5.48** | −5.95* | −5.68*** |
Relevant mechanosensitive molecules in CHP and SMG groups as compared to static controls within female and male donor cohorts. *q < 0.05, **q < 0.01, ***q < 0.001 represent statistical difference of the two groups in each fold change value.
|
| Description | Fold change: CHP/Static | Fold change: SMG/Static | ||||
|---|---|---|---|---|---|---|---|
| Female | Male | Combined | Female | Male | Combined | ||
|
| Caveolin 1 | 1.92* | 1.51 | 1.68** | 1.40 | 1.40 | 1.40* |
|
| Caveolin 2 | 1.42* | 1.28 | 1.34** | 1.07 | −1.15 | −1.04 |
|
| FosB Proto-Oncogene, AP-1 Transcription Factor Subunit | 137.8* | 9.70 | 49.48** | 2.82 | 3.66 | 3.40 |
|
| Piezo Type Mechanosensitive Ion Channel Component 1 | 1.19 | 1.41 | 1.30 | -1.02 | 1.09 | 1.04 |
|
| RUNX Family Transcription Factor 2 | 1.13 | −1.13 | 1.02 | −1.14 | 1.07 | −1.04 |
|
| Transmembrane Protein 63A | −1.05 | −1.13 | −1.09 | 1.15 | 1.22 | 1.19 |
|
| Transmembrane Protein 63B | 1.04 | 1.18 | 1.11 | 1.25 | 1.38 | 1.32 |
|
| Transmembrane Protein 63C | 1.43 | 1.42 | 1.43 | −1.24 | −1.20 | −1.22 |
|
| Transient Receptor Potential Cation Channel Subfamily V Member 1 | −1.62 | −1.21 | −1.37 | −1.16 | −1.03 | −1.08 |
|
| Transient Receptor Potential Cation Channel Subfamily V Member 4 | 1.25 | 1.02 | 1.11 | −1.10 | −1.16 | −1.13 |